menu
    • menu
    [{"orgOrder":0,"company":"Stempeutics","sponsor":"Stempeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Adult Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Stempeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stempeutics \/ Stempeutics","highestDevelopmentStatusID":"8","companyTruncated":"Stempeutics \/ Stempeutics"},{"orgOrder":0,"company":"Stempeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Adult Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Stempeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stempeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stempeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stempeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"INDIA","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Stempeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stempeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stempeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stempeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Stempeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stempeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Stempeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stempeutics","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"Allogeneic Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Stempeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stempeutics \/ Stempeutics","highestDevelopmentStatusID":"15","companyTruncated":"Stempeutics \/ Stempeutics"},{"orgOrder":0,"company":"Stempeutics","sponsor":"Stempeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Stempeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stempeutics \/ Stempeutics","highestDevelopmentStatusID":"7","companyTruncated":"Stempeutics \/ Stempeutics"},{"orgOrder":0,"company":"Stempeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Stempeucel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stempeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stempeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stempeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stempeutics","sponsor":"Novumcella","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Stempeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stempeutics \/ Novumcella","highestDevelopmentStatusID":"15","companyTruncated":"Stempeutics \/ Novumcella"},{"orgOrder":0,"company":"Stempeutics","sponsor":"Medinet","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Cell & Gene Therapy","year":"2025","type":"Licensing Agreement","leadProduct":"Allogeneic Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Stempeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stempeutics \/ MEDINET","highestDevelopmentStatusID":"15","companyTruncated":"Stempeutics \/ MEDINET"}]

    Find Clinical Drug Pipeline Developments & Deals by Stempeutics

    Menu

    Stempeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Mesenchymal Stromal Cell

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Medinet

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medinet Japan, Stempeutics India Sign License Deal for Stempeucel in Japan

                            Details : Through the licensing deal, Allogeneic Mesenchymal Stromal Cell will be utilized to address Chronic Limb Threatening Ischaemia Disease (CLTI).

                            Product Name : Stempeucel

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            October 27, 2025

                            Lead Product(s) : Allogeneic Mesenchymal Stromal Cell

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Medinet

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Mesenchymal Stromal Cell

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Cipla

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cipla and Stempeutics Collaborate for Launch ofStempeucel®, First ‘Made in India’ Cell Therapy toTreat Cr...

                            Details : Stempeucel® has been developed by Stempeutics and is the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment. Cipla will market and distribute in Stem...

                            Product Name : Stempeucel

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            August 20, 2020

                            Lead Product(s) : Allogeneic Mesenchymal Stromal Cell

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Cipla

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Novumcella

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Stempeutics Inks Pact with Novumcella for Development Co-Operation of Stempeucel to Treat CLI Due to Buergerâ€...

                            Details : As per the agreement, Novumcella will initially provide regulatory support services to Stempeutics for getting approval from PMDA, Japan for conduct of bridge study in Japan for commercializing Stempeucel® product for Buerger’s Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 28, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Novumcella

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stempeucel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disea...

                            Details : Stempeucel is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chronic Limb-Threatening Ischemia-associated with Thromboangiitis Obliterans.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 17, 2017

                            Lead Product(s) : Stempeucel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Mesenchymal Stem Cell

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis

                            Details : Allogeneic Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Liver Cirrhosis, Alcoholic.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 03, 2012

                            Lead Product(s) : Allogeneic Mesenchymal Stem Cell

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Mesenchymal Stromal Cell,Allogeneic Mesenchymal Stem Cell

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem C...

                            Details : Stempeucel (Allogeneic Mesenchymal Stem Cell) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chronic Limb-Threatening Ischemia.

                            Product Name : Stempeucel

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 02, 2011

                            Lead Product(s) : Allogeneic Mesenchymal Stromal Cell,Allogeneic Mesenchymal Stem Cell

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adult Allogeneic Mesenchymal Stem Cell

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic Mesenchymal Stem Cells in Osteoarthritis

                            Details : Adult Allogeneic Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 18, 2011

                            Lead Product(s) : Adult Allogeneic Mesenchymal Stem Cell

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adult Allogeneic Mesenchymal Stem Cell

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Stempeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic Mesenchymal Stem Cells for Osteoarthritis

                            Details : Adult Allogeneic Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 07, 2011

                            Lead Product(s) : Adult Allogeneic Mesenchymal Stem Cell

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Stempeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed

                            Stempeutics

                            India arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesenchymal Stem Cell

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Stempeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ex Vivo Cultured Adult Allogenic MSCs in Ischemic Cerebral Stroke

                            Details : Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Stroke.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 24, 2010

                            Lead Product(s) : Mesenchymal Stem Cell

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Stempeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth